Balaji Amines Limited received a Directions and Warning Letter from the Food & Drug Administration, Pune, dated January 10, 2025. The regulatory action stems from the misuse of a technical grade chemical consignment by a third party, though the company faces no monetary penalty or prosecution.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company clarified that it sold a consignment of Propylene Glycol, designated for industrial use only, to a customer. Without Balaji Amines' knowledge or consent, the customer resold the material to a third party who utilized it for pharmaceutical purposes. This usage contravened provisions of the Drugs and Cosmetics Act, 1940.

Regulatory Action Details

The FDA issued a strict warning but did not impose any fine, initiate prosecution, or pass any adverse order against the listed entity. The company stated that there is no material impact on its financials, operations, or other activities resulting from this communication.

To prevent recurrence, Balaji Amines has reviewed its sales and documentation practices. Key corrective measures include:

• Clearly stating the intended end-use on invoices and labels.
• Obtaining end-use declarations from customers prior to sale.

Disclosure Timeline and Compliance

The company disclosed this event on October 1, 2026, following a directive from SEBI. In its explanation for the delay, Balaji Amines noted that it initially viewed the warning letter as falling outside the ambit of events requiring mandatory disclosure under Sub-para 20 of Para A of Part A of Schedule III of the SEBI LODR Regulations. The company submitted the disclosure after receiving a specific letter from SEBI dated September 29, 2026.

What the Numbers Show

The incident highlights a supply chain integrity risk rather than a direct operational failure by the manufacturer. While the company maintained that the product was sold strictly for industrial use, the downstream diversion to pharmaceutical applications triggered regulatory scrutiny. The absence of a financial penalty suggests the regulator accepted the company's lack of direct involvement in the misuse, focusing instead on future preventive controls.

Balaji Amines Limited disclosed that Rajendrakumar Mohanprasad Tapadiya concluded his tenure as Independent Director of its material subsidiary, Balaji Speciality Chemicals Limited. The cessation took effect from the close of business hours on September 28, 2026.

The departure follows the completion of his second term on the subsidiary's board. The filing was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Cessation Details

The company confirmed that Tapadiya served as an Independent Director at Balaji Speciality Chemicals Limited from September 28, 2026, until the conclusion of his term on the same date. His role ended officially upon the expiry of the second term allowed under regulatory norms for independent directors.

The Board and Management of Balaji Speciality Chemicals extended their appreciation for his contributions during the tenure. No resignation letter was filed, as the exit was due to the natural expiration of the appointment period rather than a voluntary resignation or removal.

Regulatory Disclosure

The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited. The details provided align with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding director appointments and cessations.

Corporate Governance Context

Balaji Amines operates through multiple manufacturing units across Maharashtra and Telangana. The governance structure includes oversight of material subsidiaries such as Balaji Speciality Chemicals. The completion of a second term for an independent director is a standard procedural event in corporate governance cycles, ensuring periodic refreshment of board perspectives.